Levosimendan Altan

Levosimendan, the active ingredient in Levosimendan Altan, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It treats acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Altan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Severe left‑ventricular systolic dysfunction: enhances contractility and reduces filling pressures. Post‑cardiac surgery low‑output syndrome: supports hemodynamics when conventional therapy is insufficient.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: often transient during infusion. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate. - Dizziness: related to blood pressure changes. - Flushing: warm sensation on skin.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes. - Pulmonary edema: worsening respiratory status. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests.

When administering Levosimendan, several safety considerations should be observed.

Cardiovascular monitoring: continuously monitor blood pressure and heart rate during infusion. Renal impairment: adjust infusion rate or consider alternative therapy in severe renal dysfunction. Hepatic impairment: use with caution in patients with significant liver disease. Concomitant vasodilators: avoid excessive hypotension by adjusting doses. Electrolyte disturbances: correct potassium and magnesium abnormalities before starting therapy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other cardiovascular agents, requiring careful management.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Phosphodiesterase inhibitors (e.g., milrinone): risk of severe hypotension. - Beta‑blockers: may blunt the intended inotropic response.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor for excessive blood pressure drop. - Diuretics: watch electrolyte levels and volume status. - Calcium channel blockers: observe for bradycardia or conduction abnormalities.